Hologic HOLX shares were trading higher Tuesday after Cowen upgraded the stock from Market Perform to Outperform and announced a price target of $64 per share.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: breast health (44% of sales), diagnostics (39%) surgical (14%), and skeletal health (3%).
While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (74%), followed by Europe (12%), Asia (9%), and other international markets (5%). Hologic is headquartered in Bedford, Massachusetts.
Hologic shares were trading up 6.75% at $56.93 at the time of publication Tuesday. The stock has a 52-week high of $56.75 and a 52-week low of $26.49.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.